drugset / Trial / NCT02348359
X-82 to Treat Age-related Macular Degeneration
Phase 2
Terminated
157 enrolled
Tyrogenex
International Drug Development Institute · collabSynteractHCR · collab
RandomizedSingle-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of X-82 in the treatment of vision loss due to wet AMD.
Timeline
- Start
- 2015-03-16
- Primary completion
- 2017-12-12
- Completion
- 2018-01-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CM082 | Unknown | 50 mg | — |
| Subject | CM082 | Unknown | 100 mg | — |
| Subject | CM082 | Unknown | 200 mg | — |
| Background | Aflibercept | Protein / enzyme biologic | — | Intravitreal |
| Background | Bevacizumab | Monoclonal antibody | — | Intravitreal |
| Background | Ranibizumab | Monoclonal antibody | — | Intravitreal |